CNIC is an international research Centre of excellence, which mission is to improve cardiovascular health in the population, generating scientific knowledge and efficiently translating that Knowledge to the clinic. The CNIC’s three main areas of activity are Basic Research of excellence, Translational Medicine, and Training (www.cnic.es). CNIC excellence is based, among others, on its Technical Units, which are equipped with the highest state-of-the-art technology, especially in imaging issues. In 2011, the CNIC was awarded with the “Severo Ochoa” Programme by the Spanish government in recognition of its leading international standing in cardiovascular research.
CNIC headquarters, a total area of 28,144 m2, have the most modern equipment and facilities of its kind. Currently, CNIC research staff is around 345. Research is organized into 3 strategic departments: Vascular Biology & Inflammation, Cardiovascular Development & Repair and Epidemiology, Atherothrombosis & Imaging. Top-quality technical support is provided by ten technical Units including: Cellomics; Molecular and Functional Imaging; Proteomics; Genomics; Transgenesis, Animal Facility (one of the largest animal facilities in Europe, including a farm for housing pigs), Pluripotent Cell Technology, Viral Vectors, Bioinformatics and the Advanced Imaging Unit (AIU) equipped with state-of the art technology, developed by our technology partner Phillips (with an investment of more than €30M). Thanks to AIU, CNIC will be the first centre in the world to clinically validate novel diagnostic techniques in the field of preclinical and human cardiovascular imaging. See: http://www.cnic.es/en/unidades/. In addition, researchers have direct support through specialized Department Managers and Services such as: project & technology transfer office, scientific training, communication, revision and English editing, library, bio-security and radiation protection.
CNIC is the Coordinator of SECURE and as such in charge of the scientific management and representation of the project. Previously, CNIC led the FOCUS (Fixed-dose Combination Drug for Secondary Cardiovascular Prevention) study, funded under the Seventh Framework Programme. CNIC has an extended experience in the Clinical trials management thanks to several translational projects performed in the centre.
|Valentin Fuster, MD: Dr. Fuster currently combines functions as General Director of the National Centre for Cardiovascular Research Carlos III (CNIC) in Madrid and Director of the Cardiovascular Institute and Physician-in-Chief at the Mount Sinai Medical Centre, New York. He has published over 900 articles on cardiovascular research, and, besides being Doctor Honoris Causa by more than 30 universities, has received numerous scientific, academic and social recognition, among which Prince of Asturias Award for Technical and Scientific Research. Since 2014, Dr. Fuster is also chief editor of the prestigious Journal of the American College of Cardiology in the United States, where he has received numerous research grants awarded by the National Institutes of Health. He has been President of the World Heart Federation (WHF) and the American Heart Association (AHA) and leads the promotion of healthy habits advising governments of many developing countries and internationally recognized scientific projects in the area.
Dr. Fuster is currently involved in European and international projects such as PESA, WHS, METOCARD-CNIC, among others. His keys contributions are related to major findings in interdisciplinary biomedical research in atherothrombotic disease and to the translation of such findings to the resolution of the clinical problems in humans.
|Jose M. Castellano, MD, PhD: Dr. Castellano has a BSc from Brown University, Providence, Rhode Island, USA. He gained his medical degree in 2005 from the University Clinic of Navarra, Pamplona, Spain. Dr. Castellano completed a fellowship in Cardiology at the University Clinic of Navarra in 2010 and was awarded a PhD in cardiovascular medicine. In 2010 he moved to NYC to work at Mount Sinai Medical Center under the direction of Dr. Fuster, where he attained his Senior Post-Doctoral Investigator degree and holds a position as Adjunct Professor of Medicine and Cardiology. Currently, Dr. Castellano works at CNIC as coordinator of clinical research trials, Director of the Cardiovascular Health Program at Hospital Universitario Monteprincipe and Associate Professor at CEU San Pablo School of Medicine.|
|Héctor Bueno is Research Director of the Multidisciplinary Translational Cardiovascular Research (MTCR) Group at CNIC and Scientific Director of the Cardiology Department in Hospital Universitario 12 de Octubre, both in Madrid, and serves as Associate Professor of Medicine in Universidad Complutense de Madrid. He is a specialist in clinical cardiology, acute and chronic, with a focus on the evaluation and improvement of quality of care and the development of new models of care. Héctor Bueno obtained his MD at Universidad de Navarra, Spain in 1988, completed his training in Cardiology at Hospital General Universitario Gregorio Marañón, in Madrid, and obtained his PhD with the extraordinary award for the best thesis of year 1996 by Universidad Complutense de Madrid. He also obtained a degree on Design and Statistics in Health Sciences by Universitat Autónoma de Barcelona, and a degree in Integrated Health Care Systems Direction at ESADE Bussiness School, Madrid. In 2008, he served as Visiting Professor at Yale Medical School (New Haven, USA) where he worked on a Medicare Program for the development and analysis of performance measures for cardiac diseases (MI, HF). Dr. Bueno worked as Head of Clinical Cardiology in the Department of Cardiology, Hospital General Universitario Gregorio Marañón in Madrid until 2015. Dr. Bueno is currently President of the Acute Cardiovascular Care Association (ACCA) of the European Society of Cardiology. He has long experience in international expert panels and advisory boards for scientific, strategic and commercial planning and organization. He also has a long career in individual and cooperative clinical research|
|Dr. Antonio Quesada, PhD, Project Director of the SECURE trial. BS degree in Biochemistry at Granada’s University, 2000 and PhD and First Class Honours distinction from the UAM in 2005. Expert in R&D Management and regulations, including both public system (National and International) and private grants. Wide Experience in Grant Management, strategic planning and strategic decision-making processes. Quesada is University Expert in Management and Administration of Foundations. He is currently head of the Clinical Trials Coordination Unit (UCEC) at CNIC.|